CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance

Molecular Cancer Research

Volumn 7, Issue 2, 2009, Pages 168-179

  Klingbeil, Pamela ^a   Marhaba, Rachid ^a   Jung, Thorsten ^a   Kirmse, Robert ^a   Ludwig, Thomas ^a   Zöller, Margot ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF KARLSRUHE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD44V ANTIGEN; INTEGRIN; ISOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CELL ADHESION; CELL LINE; CONTROLLED STUDY; CROSS LINKING; EXON; EXTRACELLULAR MATRIX; FOOT PAD; LUNG METASTASIS; LYMPH NODE; METASTASIS; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; RAT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; ANIMALS; ANTIGENS, CD44; APOPTOSIS; BIOTINYLATION; BLOTTING, WESTERN; CELL ADHESION; CROSS-LINKING REAGENTS; EXTRACELLULAR MATRIX; FEMALE; FLOW CYTOMETRY; GENE SILENCING; IMMUNOPRECIPITATION; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MICROSCOPY, ATOMIC FORCE; PANCREATIC NEOPLASMS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, INBRED STRAINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

RATTUS;

EID: 61349189010     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0207     Document Type: Article

References (54)

1. Günthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13 -24.
2. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res 1997;71:241 -319.
3. Marhaba R, Zoller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 2004;35:211 -31.
4. Sales KM, Winslet MC, Seifalian AM. Stem cells and cancer: an overview. Stem Cell Rev 2007;3:249 -55.
5. Zou GM. Cancer stem cells in leukemia, recent advances. J Cell Physiol 2007; 213:440-4.
6. Li F, Tiede B, Massague J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 2007;17:3 -14.
7. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure ofDNAencoding the lymphocyte homing receptorCD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci U S A 1992;89:12160 -4.
8. Lynch KW. Consequences of regulated pre-mRNA splicing in the immune system. Nat Rev Immunol 2004;4:931 -40.
9. Ponta H, Sherman L, Herrlich P. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33 -45.
10. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004;4:528 -39.
11. Steeber DA, Venturi GM, Tedder TF. A new twist to the leukocyte adhesion cascade: intimate cooperation is key. Trends Immunol 2005;26:9 -12.
12. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990;61:1303 -13.
13. Bourguignon LY, Zhu H, Shao L, Zhu D, Chen YW. Rho-kinase (ROK) promotes CD44(v3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell Motil Cytoskeleton 1999;43:269 -87.
14. Tsukita S, Yonemura S, Tsukita S. ERM proteins: head-to-tail regulation of actin-plasma membrane interaction. Trends Biochem Sci 1997;22:53 -8.
15. Oliferenko S, Kaverina I, Small JV, Huber LA. Hyaluronic acid (HA) binding to CD44 activates Rac1 and induces lamellipodia outgrowth. J Cell Biol 2000;148:1159-64.
16. Lesley J, English NM, Gal I, Mikecz K, Day AJ, Hyman R. Hyaluronan binding properties of a CD44 chimera containing the link module of TSG-6. J Biol Chem 2002;277:26600-8.
17. Nandi A, Estess P, Siegelman M. Bimolecular complex between rolling and firm adhesion receptors required for cell arrest; CD44 association with VLA-4 in T cell extravasation. Immunity 2004;20:455 -65.
18. Napier SL, Healy ZR, Schnaar RL, Konstantopoulos K. Selectin ligand expression regulates the initial vascular interactions of colon carcinoma cells: the roles of CD44v and alternative sialofucosylated selectin ligands. J Biol Chem 2007;282:3433 -41.
19. 1 integrin and CD44 triple-helical ligands derived from type IV collagen. J Biol Chem 2004;279:43503-13.
20. Yu Q, Stamenkovic I. Transforming growth factor-β facilitates breast carcinoma metastasis by promoting tumor cell survival. Clin Exp Metastasis 2004;21:235 -42.
21. Ghatak S, Misra S, Toole BP. Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem 2005;280:8875 -83.
22. Bourguignon LY, Zhu H, Zhou B, Diedrich F, Singleton PA, Hung MC. Hyaluronan promotes CD44v3-2 interaction with Grb2-185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth. J Biol Chem 2001;276:48679-92.
23. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 2002;16:3074-86.
24. Marhaba R, Bourouba M, Zöller M. CD44v6 promotes proliferation by persisting activation of MAP kinases. Cell Signal 2005;17:961 -73.
25. Ghatak S, Misra S, Toole BP. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem 2002;277:38013 -20.
26. Bourguignon LY, Singleton PA, Zhu H, Diedrich F. Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J Biol Chem 2003;278:29420 -34.
27. Lee JL, Wang MJ, Sudhir PR, Chen GD, Chi CW, Chen JY. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN- CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res 2007;67:2089-97.
28. Marhaba R, Bourouba M, Zöller M. CD44v7 interferes with activation- induced cell death by up-regulation of anti-apoptotic gene expression. J Leukoc Biol 2003;74:135 -48.
29. Matzku S, Komitowski D, Mildenberger M, Zöller M. Characterization of BSp73, a spontaneous rat tumor and its in vivo selected variants showing different metastasizing capacities. Invasion Metastasis 1983;3:109-23.
30. Matzku S, Werling HO, Waller C, Schmalenberger B, Zankl H. Clonal analysis of diversity in the BSp73 rat tumor. Invasion Metastasis 1985;5:356-70.
31. Matzku S, Wenzel A, Liu S, Zöller M. Antigenic differences between metastatic and nonmetastatic BSp73 rat tumor variants characterized by monoclonal antibodies. Cancer Res 1989;49:1294-9.
32. König H, Moll J, Ponta H, Herrlich P. Trans-acting factors regulate the expression of CD44 splice variants. EMBO J 1996;15:4030-9.
33. Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: changing views. J Pathol 2008;214:283 -93.
34. Cretu A, Brooks PC. Impact of the non-cellular tumor microenvironment on metastasis: potential therapeutic and imaging opportunities. J Cell Physiol 2007;213:391 -402.
35. Natarajan TG, FitzGerald KT. Markers in normal and cancer stem cells. Cancer Biomark 2007;3:211 -31.
36. Neuzil J, Stantic M, Zobalova R, et al. Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name? Biochem Biophys Res Commun 2007;355:855-9.
37. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563 -72.
38. Goswami A, Ranganathan P, Rangnekar VM. The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target. Cancer Res 2006;66:2889-92.
39. Bates RC, Edwards NS, Burns GF, Fisher DE. CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res 2001;61:5275 -83.
40. Sohara Y, IshiguroN, Machida K, et al. Hyaluronan activates cell motility of v-Src-transformed cells via Ras-mitogen-activated protein kinase and phosphoinositide 3-kinase-Akt in a tumor-specific manner. Mol Biol Cell 2001;12:1859-68.
41. Bourguignon LYW, Singleton P, Zhu H, Diedrich F. Hyaluronan-mediated. CD44 interaction with RhoGEF and Rho-kinase promotes Grb2-associated binding-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J Biol Chem 2003;278:29420 -34.
42. Marhaba R, Freyschmidt-Paul P, Zöller M. In vivo CD44-49d complex formation in autoimmune disease has consequences on T cell activation and apoptosis resistance. Eur J Immunol 2006;36:3017-32.
43. Subramaniam V, Vincent IR, Gardner H, Chan E, Dhamko H, Jothy S. CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation. Exp Mol Pathol 2007;83:207 -15.
44. Lee JL, Wang MJ, Sudhir PR, Chen JY. CD44 engagement promotes matrix- derived survival through CD44-SRC-integrin axis in lipid rafts. Mol Cell Biol. Epub ahead of print 2008 Jul 21.
45. Kamikura DM, Khoury H, Maroun C, Naujokas MA, Park M. Enhanced transformation by a plasma membrane-associated met oncoprotein: activation ofa phosphoinositide 3'-kinase-dependent autocrine loop involving hyaluronic acid and CD44. Mol Cell Biol 2000;20:3482 -96.
46. Tulasne D, Foveau B. The shadow of death on the MET tyrosine kinase receptor. Cell Death Differ 2008;15:427 -34.
47. Girish KS, Kemparaju K. Structure, evolution, and biology of the MUC4 mucin. FASEB J 2008;22:966 -81.
48. Schmidt DS, Klingbeil P, Schnölzer M, Zöller M. CD44 variant isoforms associate with tetraspanins and EpCAM. Exp Cell Res 2004;297:329 -47.
49. Shaw AR, Li L. Exploration of the functional proteome: lessons from lipid rafts. Curr Opin Mol Ther 2003;5:294-301.
50. Chen SY, Chen HC. Direct interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion. Mol Cell Biol 2006;26:5155 -67.
51. Menzel EJ, Farr C. Hyaluronidase and its substrate hyaluronan: biochemistry, biological activities and therapeutic uses. Cancer Lett 1998;131:3 -11.
52. Fjeldstad K, Kolset SO. Decreasing the metastatic potential in cancers-targeting the heparan sulfate proteoglycans. Curr Drug Targets 2005;6:665 -82.
53. Knudson CB. Hyaluronan and CD44: strategic players for cell-matrix interactions during chondrogenesis and matrix assembly. Birth Defects Res Part C Embryo Today 2003;69:174-96.
54. Stern R. Hyaluronan metabolism: a major paradox in cancer biology. Pathol Biol 2005;53:372 -82.